La chaîne d'options affiche les données clés des options sur actions de IO Biotech à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour IO Biotech..

IO Biotech (NASDAQ:IOBT) Stock, Chaîne d'Options

IO BIOTECH INC

IO Biotech

IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.

IO Biotech Inc

Press Releases

IO Biotech Presents New Data at AACR 2025 Supporting Dual Mechanism and Immune Activation of Cancer Vaccines IO102-IO103 and IO170

News

Health Care

General

IO Biotech Showcases Scientific Leadership Through Cancer Vaccines Educational Session at the American Association for Cancer Research (AACR) Annual Meeting 2025

Earnings

IO Biotech Reports First Quarter 2025 Financial Results and Business Highlights

IO Biotech Announces Participation in Cowen 6th Annual Oncology Innovation Summit and Jefferies Global Healthcare Conference

IO Biotech to Announce Topline Results of Pivotal Phase 3 Trial of Cylembio® in Combination with KEYTRUDA® (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma

IO Biotech Announces Clinical Improvement in Progression Free Survival Demonstrated in Pivotal Phase 3 Trial of Cylembio® plus KEYTRUDA® (Pembrolizumab) for the Treatment of First-line Advanced Melanoma, but Statistical Significance Narrowly Missed

Small Cap

Opinion

Biotech Stocks Rally as Oncology Market Targets $866B by 2034

IO Biotech Reports Second Quarter 2025 Financial Results and Provides Business Highlights

Biotech at a Pivotal Moment: Four Stocks Defining The Transformation (MDCX, IOBT, INSM, RNA)

INSM

IOBT

MDCX

OLMA

ONCY

PDSB

PRPH

TSX:ONC

Achieve Life Sciences, Inc. - Common Shares

Achieve Life Sciences

Alpha Cognition

Agenus

Anika Therapeutics

Avalo Therapeutics

Black Diamond Therapeutics, Inc. - Common Stock

Black Diamond Therapeutic

Cabaletta Bio

Compugen

Coherus Oncology

Climb Bio

Cardiff Oncology

Citius Oncology

Fate Therapeutics

Forte Biosciences

Genelux

TuHURA Biosciences

Inhibikase Therapeutics, Inc. - Common Stock

Inhibikase Therapeutics

Immuneering Corporation - Class A Common Stock

Immuneering

Kyverna Therapeutics, Inc. - Common Stock

Kyverna Therapeutics

Seres Therapeutics

MEI Pharma

Protalix BioTherapeutics, Inc. (DE) Common Stock

Protalix BioTherapeutics

AVITA Medical

Protara Therapeutics, Inc. - Common Stock

Protara Therapeutics

Theratechnologies

Morgan Stanley

HC Wainwright & Co.

Piper Sandler

Comments

IO Biotech

IO Biotech (IOBT) Options

No option chain data available. Please try again later

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL